The protozoan parasite Trypanosoma cruzi causes Chagas' disease in humans and produces a complex spectrum of symptoms among infected individuals. Approximately 20 million people are currently infected with T. cruzi, and an estimated 100 million individuals living in endemic areas of Central and South America are at risk of infection. At present there are no completely effective means for treatment or prevention of Chagas' disease or for diagnosis of asymptomatic infections. Results of recent work suggests that distinct subgroups of T. cruzi can be identified which may be responsible for the different symptomatic presentations of Chagas' disease (13) . Genetic polymorphism as reflected by isoenzyme electrophoretic mobility (14) , kinetoplast DNA restriction patterns (15) , total DNA content (6) , growth rates (7) (8) (9) , and infectivity for mice and tissue culture cells (4, 17) have been detected among different strains of T. cruzi. Because the identification of parasite antigens suitable for use as diagnostic and vaccine reagents has been targeted as a primary goal in Chagas' disease research, an investigation of potential heterogeneity of the surface antigens among T. cruzi strains is warranted.
Monoclonal antibodies have proven to be valuable in the identification of distinct strains of herpes simplex virus (16), feline leukemia virus (11) , and protozoans such as Leishmania sp. (12) . The development of monoclonal antibody probes which react specifically with T. cruzi subgroups would be beneficial in epidemiological and diagnostic studies. Several anti-T. cruzi monoclonal antibodies have been developed (1, 3, 10, 20 Reactivity of monoclonal antibodies with selected strains of T. cruzi. The reactivity of monoclonal antibodies 4.2 and 7.6, which were derived from mice infected with the Peru strain, was examined in Western blots and IFAs with other T. cruzi strains isolated from various geographical locations. T. cruzi Y and CL and the clonal-isolate strains Silvio X10 clone 1 and Esmeraldo clone 3, which differ in their zymodeme profiles, growth rates, and infectivity for mice (8, 9) , were selected for these experiments. Trypomastigote lysates from each of the strains were tested for reactivity with monoclonal antibodies 4.2 and 7.6 in Western blots. Monoclonal antibody 4.2 identified a polypeptide doublet in the Y strain with the same molecular weights as the polypeptide doublet observed in the Peru strain (Fig. 3) . Interestingly, the relative intensity of the bands detected by monoclonal antibody 4 tigotes of the various strains was further tested by IFA. A positive IFA was observed with trypomastigotes from both Y and Esmeraldo clone 3 strains (Fig. 4) . No fluorescence was observed when trypomastigotes of CL or Silvio X1O clone 1 strain were tested.
Monoclonal antibody 7.6 reacted with a 68-kDa polypeptide in all of the T. criuzi strains tested (data not shown).
Positive IFA reactions were observed with all strains when they were reacted with monoclonal antibody 7.6 (Fig.  4) . have shown that these proteins are essentially homogeneous among the different strains (19, 21) . Work by Zingales et al. (21) has shown that the surface iodinatable polypeptides of several different T. cruzi strains representing different zymodeme groups are remarkably constant. Also, T. cruzi (surface) polypeptides immunoprecipitated by sera from patients with Chagas' disease infected with different T. cruzi strains all presented nearly the same electrophoretic distribution pattern. This apparent lack of heterogeneity in the surface proteins is somewhat surprising given the widely heterogeneous patterns of isoenzymes, kDNA restriction patterns, and other characteristics found among T. cruzi strains. One possible explanation for the observed homogeneity of T. cruzi surface proteins is that the methods used to analyze the surface proteins lacked the sensitivity necessary to detect antigenic heterogeneity of these polypeptides among different T. cruzi strains. Monoclonal antibodies, however, provide a means for the assessment of the presence or absence of individual antigenic determinants and thus may represent better probes for assessing antigenic heterogeneity within closely related proteins than polyclonal antisera.
The results of Western blots of trypomastigote lysates of five different strains of T. cruzi probed with surface proteinspecific monoclonal antibody 4.2 indicate that heterogeneity exists among the antigens recognized by this antibody. Of the five strains tested, three (Peru, Y, and Esmeraldo clone 3) contained polypeptides that were recognized by antibody 4.2, while two strains (CL and Silvio X10/1) showed no recognition. Of particular interest are the differences in the molecular weights of antigens detected by this antibody. Inspection of the blots of Peru and Y trypomastigotes revealed that monoclonal antibody 4.2 recognizes identical protein doublets of 90 and 105 kDa in the two strains. However, the two protein bands show a clear difference in intensity. Blots of Peru strain trypomastigotes showed a relatively more intense band at 90 kDa, while blots of the Y strain showed a heavier band at 105 kDa. In blots with Esmeraldo clone 3, a single protein of 130 kDa was detected by the monoclonal antibody. It is apparent, therefore, that the antigens recognized by this monoclonal antibody can differ in both molecular weight and abundance among different strains of the parasite.
In summary, results of this study show that the surface antigen recognized by monoclonal antibody 4.2 is present in the trypomastigote but absent in the epimastigote and amastigote stages of the parasite. Also the polypeptides recognized by this antibody exhibit heterogeneity in both molecular weight and abundance among different T. cruzi strains. The epitope recognized by monoclonal antibody 4.2 is also not universally present in all strains of the parasite. In contrast, the 68-kDa antigen recognized by monoclonal 7.6 is present in the three stages of the parasite and is present in all of the five strains tested.
